Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERi-operative Selective Decontamination of the Digestive Tract to Prevent Severe Infectious Complications After Esophagectomy
2023-504144-33-01Phase 4Authorised
- Sponsor
- Radboud University Medical Center
- Start
- Mar 2024
- Modality
- Small Molecules, Peptides
- Countries
- 2
01
Overview
Phase 4, randomised trial of colistin, tobramycin, amphotericin b and nystatin in esophageal cancer, bacterial disease and mycoses (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Cumulative incidence of postoperative pneumonia within 30 days after surgery. Planned start Mar 2024; status: authorised.
02
Drugs
colistintobramycinamphotericin bnystatin
03
Conditions
esophageal cancerbacterial diseasemycoses
Beyond the preview
Go deeper on 2023-504144-33-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504144-33-01.